Literature DB >> 15492622

Minimizing the risk of endophthalmitis following intravitreous injections.

Christopher N Ta1.   

Abstract

PURPOSE: To review techniques that are important in preventing endophthalmitis following intravitreous injections based on the available evidence.
METHODS: A review of the literature regarding existing evidence that is relevant to post-injection endophthalmitis prophylaxis.
RESULTS: The available evidence regarding endophthalmitis prophylaxis is largely based on intraocular surgery, particularly cataract surgery. Despite the controversy and the paucity of evidence regarding endophthalmitis prophylaxis for intravitreous injections, it is recommended that povidone-iodine should be used prior to intravitreous injections to minimize or eliminate the presence of ocular surface bacteria. Administration of topical antibiotics may also be considered before and after the intravitreous injections. Strict adherence to aseptic techniques, including the use of an eyelide speculum is also important.
CONCLUSION: Endophthalmitic can occur following intravitreous injections. Prophylaxis with topical povidone-iodine, and possibly antibiotics, as well as adherence to aseptic technique may minimize the risk of post-injection endophthalmitis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15492622     DOI: 10.1097/00006982-200410000-00003

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  13 in total

1.  Retinal break following an intravitreal triamcinolone acetonide injection.

Authors:  Nazmiye Erol; Seyhan Topbas; Afsun Sahin
Journal:  Int Ophthalmol       Date:  2007-02-02       Impact factor: 2.031

2.  Therapeutic potential of intravitreal pharmacotherapy in retinal vein occlusion.

Authors:  Marianne L Shahsuvaryan
Journal:  Int J Ophthalmol       Date:  2012-12-18       Impact factor: 1.779

3.  Effectiveness of 1.25 % povidone-iodine combined with topical levofloxacin against conjunctival flora in intravitreal injection.

Authors:  Yasushi Ikuno; Miki Sawa; Motokazu Tsujikawa; Fumi Gomi; Naoyuki Maeda; Kohji Nishida
Journal:  Jpn J Ophthalmol       Date:  2012-06-28       Impact factor: 2.447

4.  Acute bacterial endophthalmitis after intravitreal bevacizumab injection: Case report and literature review.

Authors:  Saba Al Rashaed; Abdulaziz Rushood
Journal:  Saudi J Ophthalmol       Date:  2012-04-28

5.  Intravitreal bevacizumab therapy for neovascular age-related macular degeneration: a pilot study.

Authors:  Maura Lucy Abrahám-Marin; Carlos Fernando Cortés-Luna; Griselda Alvarez-Rivera; Myriam Hernández-Rojas; Hugo Quiroz-Mercado; Virgilio Morales-Cantón
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-09-28       Impact factor: 3.535

Review 6.  Endophthalmitis following intravitreal anti-vascular endothelial growth factor (VEGF) injection: a comprehensive review.

Authors:  Rohan Merani; Alex P Hunyor
Journal:  Int J Retina Vitreous       Date:  2015-07-21

7.  Practice patterns of ophthalmologists administering intravitreal injections in Europe: a longitudinal survey.

Authors:  Kui Huang; Marla B Sultan; Duo Zhou; Charles S Tressler; Jingping Mo
Journal:  Clin Ophthalmol       Date:  2016-12-12

8.  Alternate serotype adenovector provides long-term therapeutic gene expression in the eye.

Authors:  Melissa M Hamilton; Gordon A Byrnes; Jason G Gall; Douglas E Brough; C Richter King; Lisa L Wei
Journal:  Mol Vis       Date:  2008-12-30       Impact factor: 2.367

9.  Rate of Post-traumatic Endophthalmitis with or without Injection of Balanced Salt Solution.

Authors:  Nasrin Rafati; Mohsen Azarmina; Farid Zaeri; Shahin Yazdani; Roham Soheilian; Masoud Soheilian
Journal:  J Ophthalmic Vis Res       Date:  2013-07

10.  Acute sterile endophthalmitis following intravitreal bevacizumab: case series.

Authors:  Axel Orozco-Hernández; Ximena Ortega-Larrocea; Gustavo Sánchez-Bermúdez; Gerardo García-Aguirre; Virgilio Morales Cantón; Raul Velez-Montoya
Journal:  Clin Ophthalmol       Date:  2014-09-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.